Utilizamos cookies para mejorar la experiencia de nuestros usuarios. Al utlizar nuestra página web acepta el uso de cookies. Aceptar

Bienvenido a la mayor red profesional del sector sanitario

Publicaciones - McKinsey&Company

09 de octubre de 2013 | McKinsey&Company

An era of open information in healthcare is now under way. We have already experienced a decade of progress in digitizing medical records, as pharmaceutical companies and other organizations aggregate years of research and development data in electronic databases.  

Healthcare stakeholders now have access to promising new threads of knowledge. This information is a form of “big data,” so called not only for its sheer volume but for its complexity, diversity, and timeliness. Pharmaceutical-industry experts, payors, and providers are now beginning to analyze big data to obtain insights. 

Although these efforts are still in their early stages, they could collectively help the industry address problems related to variability in healthcare quality and escalating healthcare spend. For instance, researchers can mine the data to see what treatments are most effective for particular conditions, identify patterns related to drug side effects or hospital readmissions, and gain other important information that can help patients and reduce costs. Fortunately, recent technologic advances in the industry have improved their ability to work with such data, even though the files are enormous and often have different database structures and technical characteristics.

Many innovative companies in the private sector—both established players and new entrants—are building applications and analytical tools that help patients, physicians, and other healthcare stakeholders identify value and opportunities.

For big-data initiatives to succeed, the healthcare system must undergo some fundamental changes. The big-data revolution is in its early days, and most of the potential for value creation is still unclaimed. But it has set the industry on a path of rapid change and new discoveries; stakeholders that are committed to innovation will likely be the first to reap the rewards.

This paper will help payors, pharmaceutical companies, and providers develop proactive strategies for winning in the new environment.

Ver publicación


Fuentes Disponibles

Fuentes Disponibles